Fujifilm Diosynth Biotechnologies & Regeneron Sign Manufacturing Agreement
Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced a 10-year manufacturing supply agreement, valued at over $3 billion (€2.64 billion), with Regeneron Pharmaceuticals to provide US-based production of its industry-leading biologic medicines, which treat millions of patients worldwide.
Under the terms of the agreement, Fujifilm Diosynth Biotechnologies will provide US-based manufacturing for Regeneron over the 10-year period through current and planned expansions at its new large-scale biopharmaceutical manufacturing facility in Holly Springs, North Carolina, when the site begins operations later this year (2025).
“We are delighted to be selected as the manufacturing supply partner for Regeneron, utilizing our new state-of-the-art facility in Holly Springs, North Carolina. The Holly Springs site is part of our kojoX interconnected manufacturing network, which provides a first-of-its-kind modular approach with standardized equipment, processes, and procedures across our sites around the globe to help ensure supply chain security and seamless tech transfers,” said Lars Petersen, President and CEO, Fujifilm Diosynth Biotechnologies. “Partnering with Regeneron, a global leader in biotechnology and scientific innovation, is a true honor for us, as we bring together our exceptional teams and shared vision to make transformative medicine accessible to patients. We are honored that Regeneron has the trust and confidence in our team’s ability to help deliver capacity faster, ensuring continuity of supply for patients in need.”
“At Regeneron, we have the privilege of making some of the best and most innovative therapeutics in the industry, and we are acutely aware of Regeneron’s impact on people’s lives as we work to help treat or even cure devastating diseases,” said Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply at Regeneron. “We take our role seriously, and our decision to work with Fujifilm Diosynth Biotechnologies reflects our belief that they will meet our high standards and grow with us. We are excited about this unique relationship, and we are already working to bring capacity online at Fujifilm Diosynth Biotechnologies’ biologics manufacturing facility in Holly Springs, North Carolina.”
